{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:09:46Z","timestamp":1788455386378,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02194-5","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:19:10Z","timestamp":1753949950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A lipid metabolism-related gene signature predicts prognosis after tamoxifen treatment in ER\u2009+\u2009breast cancer and reflects tumor microenvironment heterogeneity through single-cell analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Linxiaoxi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"1","key":"2194_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"2194_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"CK Osborne","year":"1998","unstructured":"Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609\u201318.","journal-title":"N Engl J Med"},{"issue":"17","key":"2194_CR3","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/JCO.22.02900","volume":"41","author":"M Lazzeroni","year":"2023","unstructured":"Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol. 2023;41(17):3116\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2194_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496\u2013513.","journal-title":"Cancer Cell"},{"issue":"9","key":"2194_CR5","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202537","volume":"40","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhao S, Gan L, Zhuang Z. Bioinformatics analysis of prognostic value of PITX1 gene in breast cancer. Biosci Rep. 2020;40(9): BSR20202537.","journal-title":"Biosci Rep"},{"issue":"6","key":"2194_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/CAD.0000000000000943","volume":"31","author":"J Zhou","year":"2020","unstructured":"Zhou J, Li W, Ming J, Yang W, Lu L, Zhang Q, Ruan S, Huang T. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. Anticancer Drugs. 2020;31(6):558\u201366.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"2194_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226150","volume":"14","author":"A J\u00f6gi","year":"2019","unstructured":"J\u00f6gi A, Ehinger A, Hartman L, Alkner S. Expression of HIF-1\u03b1 is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. PLoS One. 2019;14(12): e0226150.","journal-title":"PLoS One"},{"issue":"1","key":"2194_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-023-01719-z","volume":"25","author":"C Lundgren","year":"2023","unstructured":"Lundgren C, Tutzauer J, Church SE, St\u00e5l O, Ekholm M, Forsare C, Nordenskj\u00f6ld B, Fern\u00f6 M, Bendahl PO, Ryd\u00e9n L. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial. Breast Cancer Res. 2023;25(1):110.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2194_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"2194_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","volume":"14","author":"M Kwa","year":"2017","unstructured":"Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14(10):595\u2013610.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2194_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","volume":"3","author":"SK Yeo","year":"2017","unstructured":"Yeo SK, Guan JL. Breast cancer: multiple subtypes within a tumor? Trends Cancer. 2017;3(11):753\u201360.","journal-title":"Trends Cancer"},{"issue":"2","key":"2194_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2217\/fon-2018-0221","volume":"15","author":"M Brand\u00e3o","year":"2019","unstructured":"Brand\u00e3o M, Pond\u00e9 N, Piccart-Gebhart M. Mammaprint\u2122: a comprehensive review. Future Oncol. 2019;15(2):207\u201324.","journal-title":"Future Oncol"},{"issue":"8","key":"2194_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"2194_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14740\/wjon1019w","volume":"8","author":"L Xin","year":"2017","unstructured":"Xin L, Liu YH, Martin TA, Jiang WG. The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint. World J Oncol. 2017;8(2):34\u201340.","journal-title":"World J Oncol"},{"issue":"23","key":"2194_CR15","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","volume":"40","author":"UA Nitz","year":"2022","unstructured":"Nitz UA, Gluz O, K\u00fcmmel S, Christgen M, Braun M, Aktas B, L\u00fcdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer. J Clin Oncol. 2022;40(23):2557\u201367.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2194_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, et al. JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27(1):136-150.e135.","journal-title":"Cell Metab"},{"issue":"4","key":"2194_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","volume":"2","author":"GB Ferraro","year":"2021","unstructured":"Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2(4):414\u201328.","journal-title":"Nat Cancer"},{"key":"2194_CR18","doi-asserted-by":"publisher","unstructured":"Menendez JA, Papadimitropoulou A, Vander Steen T, Cuy\u00e0s E, Oza-Gajera BP, Verdura S, Espinoza I, Vellon L, Mehmi I, Lupu R. Fatty acid synthase confers tamoxifen resistance to ER+\/HER2+ breast cancer. Cancers (Basel). 2021;13(5):1132.\u00a0https:\/\/doi.org\/10.3390\/cancers13051132.","DOI":"10.3390\/cancers13051132"},{"issue":"10","key":"2194_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06181-5","volume":"14","author":"C Jiang","year":"2023","unstructured":"Jiang C, Zhu Y, Chen H, Lin J, Xie R, Li W, Xue J, Chen L, Chen X, Xu S. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell Death Dis. 2023;14(10): 653.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2194_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1040-3","volume":"38","author":"X Chu","year":"2019","unstructured":"Chu X, Zhou Q, Xu Y, Jiang J, Li Q, Zhou Q, Wu Q, Jin M, Wang H, Gu Y, et al. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer. J Exp Clin Cancer Res. 2019;38(1): 100.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2194_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101009","volume":"6","author":"M Zhao","year":"2024","unstructured":"Zhao M, Yuan H, Yang G, Wang Y, Bu Y, Zhang H, Zhao L, Lv P, Yun H, Geng Y, et al. Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR\/ITGB4\/SREBP1c signalling in liver cancer. JHEP Rep. 2024;6(4): 101009.","journal-title":"JHEP Rep"},{"issue":"1","key":"2194_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29(1):83\u20136.","journal-title":"Cell Res"},{"issue":"1","key":"2194_CR23","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41467-023-41318-2","volume":"14","author":"H Sun","year":"2023","unstructured":"Sun H, Zhang L, Wang Z, Gu D, Zhu M, Cai Y, Li L, Tang J, Huang B, Bosco B, et al. Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer. Nat Commun. 2023;14(1):5590.","journal-title":"Nat Commun"},{"issue":"2","key":"2194_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304.e296.","journal-title":"Cell"},{"issue":"27","key":"2194_CR25","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","volume":"28","author":"WF Symmans","year":"2010","unstructured":"Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28(27):4111\u20139.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2194_CR26","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1158\/0008-5472.CAN-11-0489","volume":"71","author":"FM Buffa","year":"2011","unstructured":"Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. Microrna-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microrna expression profiling in breast cancer. Cancer Res. 2011;71(17):5635\u201345.","journal-title":"Cancer Res"},{"issue":"10","key":"2194_CR27","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/carcin\/bgt208","volume":"34","author":"C Clarke","year":"2013","unstructured":"Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O\u2019Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;34(10):2300\u20138.","journal-title":"Carcinogenesis"},{"issue":"9","key":"2194_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/gcc.22184","volume":"53","author":"A Kwiecinska","year":"2014","unstructured":"Kwiecinska A, Ichimura K, Berglund M, Dinets A, Sulaiman L, Collins VP, Larsson C, Porwit A, Lagercrantz SB. Amplification of 2p as a genomic marker for transformation in lymphoma. Genes Chromosomes Cancer. 2014;53(9):750\u201368.","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"2194_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2194_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"7","key":"2194_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DM Gendoo","year":"2016","unstructured":"Gendoo DM, Ratanasirigulchai N, Schr\u00f6der MS, Par\u00e9 L, Parker JS, Prat A, Haibe-Kains B. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32(7):1097\u20139.","journal-title":"Bioinformatics"},{"issue":"19","key":"2194_CR32","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","volume":"32","author":"ZL Skidmore","year":"2016","unstructured":"Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, Griffith M. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012\u20134.","journal-title":"Bioinformatics"},{"issue":"7","key":"2194_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2194_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"W1","key":"2194_CR35","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509-w514.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2194_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. Xcell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"5","key":"2194_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"6","key":"2194_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6): bbab260.","journal-title":"Brief Bioinform"},{"key":"2194_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-21","volume":"3","author":"A Gribov","year":"2010","unstructured":"Gribov A, Sill M, L\u00fcck S, R\u00fccker F, D\u00f6hner K, Bullinger L, Benner A, Unwin A. SEURAT: visual analytics for the integrated analysis of microarray data. BMC Med Genomics. 2010;3: 21.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"2194_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using cell chat. Nat Commun. 2021;12(1): 1088.","journal-title":"Nat Commun"},{"issue":"2","key":"2194_CR41","first-page":"3152","volume":"17","author":"H Zhou","year":"2018","unstructured":"Zhou H, Lv Q, Guo Z. Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years. Mol Med Rep. 2018;17(2):3152\u20137.","journal-title":"Mol Med Rep"},{"key":"2194_CR42","doi-asserted-by":"crossref","unstructured":"Gao S, Wang Y, Xu Y, Liu S. An angiogenesis-related lncRNA signature is associated with prognosis and tumor immune microenvironment in breast cancer. J Pers Med. 2023;13(3):513.","DOI":"10.3390\/jpm13030513"},{"key":"2194_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-339","volume":"8","author":"A Tutt","year":"2008","unstructured":"Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, et al. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer. 2008;8: 339.","journal-title":"BMC Cancer"},{"issue":"1","key":"2194_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4757-z","volume":"18","author":"S Hultsch","year":"2018","unstructured":"Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, Pieti\u00e4inen V, Kallioniemi O. Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer. 2018;18(1): 850.","journal-title":"BMC Cancer"},{"issue":"4","key":"2194_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3892\/ol.2021.12555","volume":"21","author":"S Kim","year":"2021","unstructured":"Kim S, You D, Jeong Y, Yoon SY, Kim SA, Lee JE. Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor \u03b1 positive breast cancer. Oncol Lett. 2021;21(4):294.","journal-title":"Oncol Lett"},{"key":"2194_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115013","volume":"247","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen Y, Jiang J, Chu X, Guo Q, Zhao L, Feng F, Liu W, Zhang X, He S, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2023;247: 115013.","journal-title":"Eur J Med Chem"},{"key":"2194_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-25","volume":"5","author":"M Mamtani","year":"2012","unstructured":"Mamtani M, Kulkarni H. Association of HADHA expression with the risk of breast cancer: targeted subset analysis and meta-analysis of microarray data. BMC Res Notes. 2012;5: 25.","journal-title":"BMC Res Notes"},{"issue":"11","key":"2194_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-017-0002-x","volume":"6","author":"JC Harrell","year":"2017","unstructured":"Harrell JC, Shroka TM, Jacobsen BM. Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer. Oncogenesis. 2017;6(11): 396.","journal-title":"Oncogenesis"},{"issue":"2","key":"2194_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1631\/jzus.B2200292","volume":"24","author":"D Yang","year":"2023","unstructured":"Yang D, Feng Y, Lu H, Chen K, Xu J, Li P, Wang T, Xia D, Wu Y. USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. J Zhejiang Univ Sci B. 2023;24(2):143\u201356.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"34","key":"2194_CR50","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41388-018-0273-5","volume":"37","author":"K Gala","year":"2018","unstructured":"Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh JJ, Berger M, et al. KMT2C mediates the estrogen dependence of breast cancer through regulation of ER\u03b1 enhancer function. Oncogene. 2018;37(34):4692\u2013710.","journal-title":"Oncogene"},{"issue":"2","key":"2194_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-021-06325-1","volume":"189","author":"X Liu","year":"2021","unstructured":"Liu X, Qiu R, Xu M, Meng M, Zhao S, Ji J, Yang Y. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. Breast Cancer Res Treat. 2021;189(2):347\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2194_CR52","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bbalip.2015.05.001","volume":"1851","author":"SA Morad","year":"2015","unstructured":"Morad SA, Cabot MC. Tamoxifen regulation of sphingolipid metabolism\u2013therapeutic implications. Biochim Biophys Acta. 2015;1851(9):1134\u201345.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2194_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clbc.2021.08.010","volume":"21","author":"D Ribatti","year":"2021","unstructured":"Ribatti D, Annese T, Tamma R. Controversial role of mast cells in breast cancer tumor progression and angiogenesis. Clin Breast Cancer. 2021;21(6):486\u201391.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2194_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1): 118.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2194_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065512","volume":"24","author":"P Wielgat","year":"2023","unstructured":"Wielgat P, Rogowski K, Czarnomysy R, Wawrusiewicz-Kurylonek N, Narejko K, Bielawski K, Car H. Tamoxifen modulates the immune landscape of the tumour microenvironment: the paired Siglec-5\/14 checkpoint in anti-tumour immunity in an in vitro model of breast cancer. Int J Mol Sci. 2023;24(6): 5512.","journal-title":"Int J Mol Sci"},{"issue":"6657","key":"2194_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F, Kiss M, Park JC, Saal TM, Hoelzl J, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515\u201324.","journal-title":"Science"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02194-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:54:25Z","timestamp":1757328865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02194-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02194-5","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}